Shares of Ascendis Pharma (NASDAQ:ASND) have received a consensus rating of “Buy” from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $67.33.
ASND has been the topic of several research analyst reports. BidaskClub raised shares of Ascendis Pharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. Credit Suisse Group reaffirmed a “buy” rating and issued a $50.00 price target on shares of Ascendis Pharma in a report on Sunday, February 25th. Zacks Investment Research raised shares of Ascendis Pharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 21st. Bank of America increased their target price on Ascendis Pharma from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Finally, Wedbush reissued an “outperform” rating and issued a $67.00 target price on shares of Ascendis Pharma in a research note on Monday, February 26th.
Shares of Ascendis Pharma stock traded up $0.59 during trading on Monday, hitting $66.88. The stock had a trading volume of 43,995 shares, compared to its average volume of 167,438. The stock has a market cap of $2.75 billion, a P/E ratio of -15.45 and a beta of 0.65. Ascendis Pharma has a 12 month low of $21.95 and a 12 month high of $70.50.
Ascendis Pharma (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, March 28th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.16). The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.58 million. Ascendis Pharma had a negative return on equity of 74.67% and a negative net margin of 8,156.09%. equities research analysts forecast that Ascendis Pharma will post -3.8 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Atria Investments LLC bought a new position in Ascendis Pharma in the first quarter valued at $212,000. Quantbot Technologies LP bought a new position in Ascendis Pharma in the first quarter valued at $215,000. Kovack Advisors Inc. bought a new position in Ascendis Pharma in the first quarter valued at $218,000. Jane Street Group LLC bought a new position in Ascendis Pharma in the first quarter valued at $250,000. Finally, JPMorgan Chase & Co. bought a new position in Ascendis Pharma in the first quarter valued at $255,000. 90.53% of the stock is currently owned by institutional investors and hedge funds.
About Ascendis Pharma
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.